Cytek Biosciences (NASDAQ:CTKB – Get Free Report) is expected to be releasing its earnings data after the market closes on Wednesday, March 12th. Analysts expect Cytek Biosciences to post earnings of $0.06 per share and revenue of $59.38 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Cytek Biosciences Trading Up 0.2 %
Shares of CTKB stock opened at $4.31 on Wednesday. The firm has a market capitalization of $555.18 million, a P/E ratio of -53.87 and a beta of 1.40. The firm’s fifty day simple moving average is $5.74 and its 200 day simple moving average is $5.74. Cytek Biosciences has a 1 year low of $4.20 and a 1 year high of $8.44.
Cytek Biosciences announced that its Board of Directors has approved a share repurchase plan on Monday, December 30th that authorizes the company to repurchase $50.00 million in shares. This repurchase authorization authorizes the company to purchase up to 5.9% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its stock is undervalued.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on CTKB
Cytek Biosciences Company Profile
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
See Also
- Five stocks we like better than Cytek Biosciences
- What is the FTSE 100 index?
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Tesla Stock: Finding a Bottom May Take Time
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.